Cargando…

The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention

BACKGROUND: Clopidogrel is an inactive prodrug, it catalyzed into its active form by Cytochrome 450 and Paraoxonase-1(PON-1). polymorphisms of genes encoding these enzymes will affect the efficacy of Clopidogrel. The main objective of our study was to investigate the association of CYP2C19*2, CYP2C1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Zhaowei, Chen, Mingxiao, Zhang, Long, Zhao, Qiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942367/ https://www.ncbi.nlm.nih.gov/pubmed/31900240 http://dx.doi.org/10.1186/s40360-019-0378-7

Ejemplares similares

Effects of Cytochrome P450 2C19 and Paraoxonase 1 Polymorphisms on Antiplatelet Response to Clopidogrel Therapy in Patients with Coronary Artery Disease
por: Tresukosol, Damrus, et al.
Publicado: (2014)

Cytochrome P450 2C19 Polymorphisms and Its Association With Major Adverse Cardiac Events in Post-coronary Intervention Patients on Clopidogrel in the Tertiary Care Center
por: Kambhampati, Nikhil Teja, et al.
Publicado: (2023)

Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response
por: Kreutz, Rolf P, et al.
Publicado: (2012)

The role of clopidogrel resistance-related genetic and epigenetic factors in major adverse cardiovascular events among patients with acute coronary syndrome after percutaneous coronary intervention
por: Giantini, Astuti, et al.
Publicado: (2023)

Proton Pump Inhibitor and Clopidogrel Use After Percutaneous Coronary Intervention and Risk of Major Cardiovascular Events
por: Maret-Ouda, John, et al.
Publicado: (2021)

New genetic variants associated with major adverse cardiovascular events in patients with acute coronary syndromes and treated with clopidogrel and aspirin
por: Liu, Xiaomin, et al.
Publicado: (2021)

Effects of paraoxonase activity and gene polymorphism on coronary vasomotion
por: Dunet, Vincent, et al.
Publicado: (2011)

Cytochrome P450 2C19 Polymorphism is Associated with Reduced Clopidogrel Response in Cerebrovascular Disease
por: Lee, Jun-Beom, et al.
Publicado: (2011)

Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel response
por: Kreutz, Rolf P, et al.
Publicado: (2013)

Association between cytochrome P450 2C19 polymorphism and clinical outcomes in clopidogrel-treated Uygur population with acute coronary syndrome: a retrospective study
por: Yu, Luhai, et al.
Publicado: (2021)

Impact of Cytochrome P450 2C19* 2 and * 3 on Clopidogrel Loading Dose in Saudi Patients with Acute Coronary Syndrome
por: Khalaf, Hassan, et al.
Publicado: (2016)

Influence of CYP450 Enzymes and ABCB1 Polymorphisms on Clopidogrel Response in Moroccan Patients with Acute Coronary Syndromes
por: Mouhrach, Ismail, et al.
Publicado: (2023)

Cytochrome P450 2C19 Polymorphism in Iranian Patients with Coronary Artery Disease
por: Akhlaghi, Arash, et al.
Publicado: (2011)

Association of ABCC2 polymorphism with clopidogrel response in Chinese patients undergoing percutaneous coronary intervention
por: Chen, Lida, et al.
Publicado: (2022)

Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke
por: Yi, Xingyang, et al.
Publicado: (2016)

Association of lipoprotein(a) and major adverse cardiovascular events in patients with percutaneous coronary intervention
por: Chen, Zhihao, et al.
Publicado: (2018)

Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention
por: Norgard, Nicholas B, et al.
Publicado: (2009)

Comparison of Ticagrelor and Clopidogrel for Patients Undergoing Emergency Percutaneous Coronary Intervention
por: YANG, Bin, et al.
Publicado: (2018)

Influence of cytochrome P450 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke previously treated with clopidogrel
por: Kitazono, Takanari, et al.
Publicado: (2018)

Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome
por: Wei, You-quan, et al.
Publicado: (2015)

Increased risk of adverse events in patients with low-on clopidogrel platelet reactivity after percutaneous coronary intervention: A systematic review and meta-analysis
por: Bálint, Alexandra, et al.
Publicado: (2022)

Association of ABCB1 Gene Polymorphisms and Clopidogrel Responsiveness in Iranian Patients undergoing Percutaneous Coronary Intervention
por: Namazi, Soha, et al.
Publicado: (2020)

A Study on the Correlation Between MDR1 Polymorphism and Clopidogrel Resistance in Hui Patients Treated with Percutaneous Coronary Intervention
por: Chen, Fang, et al.
Publicado: (2021)

The SYNTAX Score Can Predict Major Adverse Cardiac Events Following Percutaneous Coronary Intervention
por: Safarian, Hadi, et al.
Publicado: (2014)

Impact of heart failure severity and major bleeding events after percutaneous coronary intervention on subsequent major adverse cardiac events
por: Ikebe, So, et al.
Publicado: (2023)

Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention
por: Zheng, Wei, et al.
Publicado: (2019)

The Personality and Psychological Stress Predict Major Adverse Cardiovascular Events in Patients With Coronary Heart Disease After Percutaneous Coronary Intervention for Five Years
por: Du, Jinling, et al.
Publicado: (2016)

Efficacy and safety of clopidogrel only vs. clopidogrel added proton pump inhibitors in the treatment of patients with coronary heart disease after percutaneous coronary intervention: A systematic review and meta-analysis
por: Pang, Jun, et al.
Publicado: (2019)

Intronic polymorphisms of cytochromes P450
por: Ingelman-Sundberg, Magnus, et al.
Publicado: (2010)

Use of clopidogrel in the reduction of myocardial damage during percutaneous coronary intervention
por: Dasgupta, Arijit, et al.
Publicado: (2009)

Post percutaneous coronary interventional adverse cardiovascular outcomes and bleeding events observed with prasugrel versus clopidogrel: direct comparison through a meta-analysis
por: Bundhun, Pravesh Kumar, et al.
Publicado: (2018)

Risk of Major Adverse Cardiovascular Events and Major Hemorrhage Among White and Black Patients Undergoing Percutaneous Coronary Intervention
por: Cai, Anping, et al.
Publicado: (2019)

Efficacy and Safety of Ticagrelor and Clopidogrel in Patients with Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
por: Li, Jianan, et al.
Publicado: (2021)

Ticagrelor vs. Clopidogrel After Complex Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease
por: Xi, Ziwei, et al.
Publicado: (2021)

Paraoxonase gene polymorphisms: Understanding the biochemical and genetic basis of coronary artery disease
por: Nasreen, Fathima J., et al.
Publicado: (2022)

A prognostic nomogram for long-term major adverse cardiovascular events in patients with acute coronary syndrome after percutaneous coronary intervention
por: Kong, Shuting, et al.
Publicado: (2021)

Associations between P2RY12 gene polymorphisms and risks of clopidogrel resistance and adverse cardiovascular events after PCI in patients with acute coronary syndrome
por: Li, Miaonan, et al.
Publicado: (2017)

Impact of Clopidogrel Stop Interval on Major Adverse Bleeding Events in Cardiac Surgery
por: Huo, Bright, et al.
Publicado: (2021)

Aspirin in combination with clopidogrel in the treatment of acute myocardial infarction patients undergoing percutaneous coronary intervention
por: Zhang, Xiaoyan, et al.
Publicado: (2019)

Major adverse cardiovascular event (MACE) after percutaneous coronary intervention in one-year follow-up study
por: Farshidi, Hossein, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_522ist9hk6966276eibm6lmg6k